Intellia Therapeutics presented a clinical update at the ESGCT meeting reporting progress across its in vivo lipid nanoparticle (LNP) gene editing programs. CSO Birgit Schultes highlighted NTLA‑2002 for hereditary angioedema (HAE) and the transthyretin (ATTR) program, noting durable knockdown of target proteins and acceptable safety signals across treated cohorts. The HAE program produced sustained kallikrein reductions for up to two years in some patients. Intellia emphasized LNP advantages—liver targeting, transient expression, redosing potential and scalability—while reporting more than 350 treated patients across programs and published NEJM papers supporting clinical exposure. The update frames Intellia as a leader in systemic in vivo editing and sets expectations for regulators and investors monitoring durability, immune responses, and tissue specificity as the field moves beyond first approvals.